Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,564 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Utility of Ultrasound-Guided Attenuation Parameter for Grading Steatosis With Reference to MRI-PDFF in a Large Cohort.
Imajo K, Toyoda H, Yasuda S, Suzuki Y, Sugimoto K, Kuroda H, Akita T, Tanaka J, Yasui Y, Tamaki N, Kurosaki M, Izumi N, Nakajima A, Kumada T. Imajo K, et al. Among authors: tamaki n. Clin Gastroenterol Hepatol. 2022 Nov;20(11):2533-2541.e7. doi: 10.1016/j.cgh.2021.11.003. Epub 2021 Nov 10. Clin Gastroenterol Hepatol. 2022. PMID: 34768008 Free article.
A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis.
Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Ikeda H, Itakura J, Takahashi Y, Asahina Y, Higaki M, Enomoto N, Izumi N. Kurosaki M, et al. Among authors: tamaki n. Hepatol Res. 2010 Apr;40(4):251-60. doi: 10.1111/j.1872-034X.2009.00607.x. Epub 2010 Jan 11. Hepatol Res. 2010. PMID: 20070391
Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy.
Kurosaki M, Hosokawa T, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Kurosaki M, et al. Among authors: tamaki n. Hepatol Res. 2010 Sep;40(9):870-7. doi: 10.1111/j.1872-034X.2010.00692.x. Hepatol Res. 2010. PMID: 20887591
Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy.
Itakura J, Asahina Y, Tamaki N, Hirayama I, Yasui Y, Tanaka T, Sato M, Ueda K, Kuzuya T, Tsuchiya K, Nakanishi H, Kurosaki M, Gabriel GS, Schneider GJ, Izumi N. Itakura J, et al. Among authors: tamaki n. Hepatol Res. 2011 Mar;41(3):217-24. doi: 10.1111/j.1872-034X.2010.00768.x. Hepatol Res. 2011. PMID: 21338453
Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
Kurosaki M, Tanaka Y, Tanaka K, Suzuki Y, Hoshioka Y, Tamaki N, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Matsuura K, Sugauchi F, Enomoto N, Nishida N, Tokunaga K, Mizokami M, Izumi N. Kurosaki M, et al. Among authors: tamaki n. Antivir Ther. 2011;16(5):685-94. doi: 10.3851/IMP1796. Antivir Ther. 2011. PMID: 21817190
Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.
Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, Tamaki N, Hoshioka Y, Yasui Y, Katoh T, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nitta S, Sakamoto N, Izumi N. Asahina Y, et al. Among authors: tamaki n. Hepatology. 2012 Jan;55(1):20-9. doi: 10.1002/hep.24623. Epub 2011 Nov 29. Hepatology. 2012. PMID: 21898478
1,564 results